生物技术公司MeiraGTx Holdings Plc与医疗保健巨头强生达成一项关于基因疗法Bota-Vec的授权协议。根据协议条款，MeiraGTx将向强生支付包括2500万美元首付款、后续里程碑款项以及高达两位数百分比的特许权使用费在内的多重财务对价。
此次交易涉及的治疗方案Bota-Vec是一款处于研发阶段的基因疗法，其具体适应症未在公告中披露。高额的特许权使用费条款凸显了该疗法在商业化后的潜在市场价值。协议中的里程碑付款将与该疗法研发进程中的关键节点挂钩，这种支付结构在生物医药领域的授权合作中较为常见。
通过获得Bota-Vec的权益，MeiraGTx有望进一步拓展其基因治疗产品管线。而对于强生而言，此次授权交易则体现了其通过外部合作优化研发资产组合的战略方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.